Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts

EuroIntervention

Volumn 4, Issue 3, 2008, Pages 311-317

  Van Twisk, Piet Hein ^a   Daemen, Joost ^a   Kukreja, Neville ^a   Van Domburg, Ron T ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bare metal stent; Bypass graft; Drug eluting stent; Long term safety

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; METAL;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEVICE SAFETY; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; SURVIVAL RATE; TARGET VESSEL REVASCULARIZATION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VEIN GRAFT DISEASE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; GRAFT OCCLUSION; KAPLAN MEIER METHOD; MIDDLE AGED; RESTENOSIS; SAPHENOUS VEIN; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY DISEASE; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; PACLITAXEL; SAPHENOUS VEIN; SIROLIMUS; TREATMENT OUTCOME;

EID: 59049086905     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV4I3A57     Document Type: Article

References (27)

1. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294(19):2446-2454.
2. FitzGibbon GM, Leach AJ, Kafka HP, Keon WJ. Coronary bypass graft fate: long-term angiographic study. J Am Coll Cardiol. 1991;17(5):1075-1080.
3. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28(3):616-626.
4. Baim DS. Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. J Am Coll Cardiol. 2003;42(8):1370-1372.
5. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito R. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40(11):1951-1954.
6. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, Serruys PW. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol. 1996;28(1):89-96.
7. Keeley EC, Velez CA, O’Neill WW, Safian RD. Long-term clinical out-comeandpredictorsofmajoradversecardiaceventsafterpercutaneousinter-ventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38(3):659-665.
8. Costa R. Long-term clinical outcomes (up to five years) of unselected high-risk patients treated with drug-eluting stents - results from the prospective, non-randomized DESIRE (Drug-Eluting Stents In the REal world) Registry. Paper presented at: Transcatheter Cardiovascular Therapeutics, 2007; Washington, DC.
9. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48(12):2423-2431.
10. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66(4):507-511.
11. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 2007;93(3):331-334.
12. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50(3):261-267.
13. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109(2):190-195.
14. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45(6):947-953.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
16. WHO. International Statistical Classification of Diseases and Related Health Problems. 10th revision. Paper presented at: Geneva: WHO, 1992.
17. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-948.
18. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):1030-1039.
19. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45(7):989-994.
20. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007;99(8):1027-1032.
21. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2007;28(1):26-32.
22. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989-997.
23. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998-1008.
24. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357(14):1393-1402.
25. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009-1019.
26. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet. 2007;370(9598):1552-1559.
27. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440-1455; discussion 1455.